European CHMP Adopts Positive Opinion for Treatment of All Genotypes of Chronic Hepatitis C

3 June 2016
189 Views

Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), has adopted a positive opinion on the company’s Marketing Authorization Application (MAA) for an investigational, pan-genotypic, once-daily tablet containing the nucleotide analogue polymerase inhibitor sofosbuvir (SOF) 400 mg and velpatasvir (VEL) 100 mg, an investigational pan-genotypic NS5A inhibitor, for the treatment of chronic hepatitis C virus (HCV) infection. The data included in the application support the use of Epclusa (SOF/VEL) in adults with all genotypes (GT1-6) of HCV infection.

The CHMP positive opinion was adopted following an accelerated review procedure, reserved for medicinal products expected to be of major public health interest. The recommendation will now be reviewed by the European Commission, which has the authority to approve medicines for use in the 28 countries of the European Union, Norway and Iceland.

You may be interested

Regling: “We are ready to ease the Greek debt”
FINANCE
shares34 views
FINANCE
shares34 views

Regling: “We are ready to ease the Greek debt”

makis - Feb 23, 2018

Technical work has begun to determine whether Greece will need a debt relief after an expected exit from the rescue…

Turkey threatens violence against Italian drill ship anew in Cyprus!
GREECE
shares48 views
GREECE
shares48 views

Turkey threatens violence against Italian drill ship anew in Cyprus!

makis - Feb 23, 2018

Turkey continued its belligerent stance off the coast of Cyprus on Friday, as it openly threatened violence against the Italian…

Greek PM Tsipras met with German Chancellor Merkel on EU Summit sidelines
POLITICS
shares41 views
POLITICS
shares41 views

Greek PM Tsipras met with German Chancellor Merkel on EU Summit sidelines

makis - Feb 23, 2018

Greek PM Alexis Tsipras met with German Chancellor Angela Merkel on the sidelines of the Brussels EU Summit, Thursday. According…

Leave a Comment

Your email address will not be published.